Article
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Apr 2024
Ganz Patricia A, Bandos Hanna, Španić Tanja, Friedman Sue, Müller Volkmar, Kuemmel Sherko, Delaloge Suzette, Brain Etienne, Toi Masakazu, Yamauchi Hideko, de Dueñas Eduardo-M, Armstrong Anne, Im Seock-Ah, Song Chuan-Gui, Zheng Hong, Sarosiek Tomasz, Sharma Priyanka, Geng Cuizhi, Fu Peifen, Rhiem Kerstin, Frauchiger-Heuer Heike, Wimberger Pauline, t'Kint de Roodenbeke Daphné, Liao Ning, Goodwin Annabel, Chakiba-Brugère Camille, Friedlander Michael, Lee Keun Seok, Giacchetti Sylvie, Takano Toshimi, Henao-Carrasco Fernando, Virani Shamsuddin, Valdes-Albini Frances, Domchek Susan M, Bane Charles, McCarron Edward C, Mita Monica, Rossi Giovanna, Rastogi Priya, Fielding Anitra, Gelber Richard D, Scheepers Elsemieke D, Cameron David, Garber Judy, Geyer Charles E, Tutt Andrew N J
Abstract excerpt
PURPOSE: The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline BRCA1/2, high-risk human epidermal growth factor receptor 2-negative early breast cancer after completing (neo)adjuvant chemotherapy ([N]ACT), surgery, and radiotherapy. The patient-reported outcome primary hypothesis was that OL-treated patients may experience greater...
Read the complete abstract on PubMed